Innovation PotentialThe partial response in a heavily pretreated PD-1 refractory patient is an achievement, representing the potential of CHS-114 to potentially overcome PD-1 resistance.
Regulatory MomentumThe National Comprehensive Cancer Network (NCCN) revised guidelines include Loqtorzi as the preferred regimen.
Strategic TransitionCoherus has made significant positive progress as it has completed its transition to a novel oncology company, including what is considered an attractive sale of its biosimilar business, allowing the company to extinguish its debt and provide funding for the next ~18 months as it executes on driving Loqtorzi sales.